Martin Berk, MD
Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1033118278
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $333,065 of the $379,175 with a category attached, or 87.8%. 27 manufacturers reported payments, led by Johnson & Johnson at 31.3% of the total. Reporting peaked in 2024 at $94,651 and has fallen 54.1% since, to $43,478 in 2025. Among advanced heart failure and transplant cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $977.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$119K
- Novo Nordisk$116K
- Merck$82K
- Boehringer Ingelheim$28K
- Novartis$16K
- Lilly USA, LLC$9K
- plus $10K from 21 others
Across 841 payments — averaging $1770.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$342K
- Janssen Research & Development, LLC$247K
- American Regent$196K
- Novartis$155K
- AstraZeneca$100K
- Cvrx, Inc.$82K
- plus $367K from 8 others
What the payments were for
- Consulting fees$8,5902%
- Speaking & faculty fees$333,06588%
- Travel & lodging$30,0288%
- Food & beverage$7,3212%
- Education$1700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 110 | $118,780 |
| Novo Nordisk | 61 | $115,694 |
| Merck | 71 | $82,140 |
| Boehringer Ingelheim | 30 | $27,600 |
| Novartis | 24 | $16,495 |
| Lilly USA, LLC | 10 | $8,877 |
| Esperion Therapeutics, Inc. | 5 | $5,938 |
| Bayer | 6 | $1,037 |
| Boston Scientific | 11 | $712 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $336 |
| Heartflow, Inc. | 3 | $263 |
| Amgen | 10 | $198 |
| Abbott | 2 | $193 |
| Inspire Medical Systems, Inc. | 1 | $145 |
| Idorsia Pharmaceuticals US Inc | 2 | $121 |
| Pfizer | 4 | $121 |
| Kestra Medical Technology Services, Inc. | 3 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| AstraZeneca | 2 | $58 |
| Itamar Medical Inc | 2 | $46 |
| Bard Peripheral Vascular, Inc. | 1 | $42 |
| Amarin Pharma, Inc. | 2 | $41 |
| Siemens Medical Solutions USA, Inc. | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$379,175 in reported general payments places this provider in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 442 | $409,852 |
| EntrestoSacubitril/Valsartan | 229 | $267,881 |
| EliquisApixaban | 248 | $267,287 |
| XareltoRivaroxaban | 190 | $234,883 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 91 | $79,581 |
| TrulicityDulaglutide | 36 | $41,945 |
| NexlizetBempedoic Acid/Ezetimibe | 50 | $39,222 |
| VerquvoVericiguat | 30 | $37,986 |
| FarxigaDapagliflozin Propanediol | 37 | $33,511 |
| OzempicSemaglutide | 26 | $29,336 |
| Repatha SureclickEvolocumab | 33 | $26,057 |
| Ezetimibe | 754 | $19,582 |
| MounjaroTirzepatide | 17 | $18,284 |
| BrilintaTicagrelor | 12 | $13,270 |
| Rosuvastatin Calcium | 801 | $10,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $27,600 | $489,433533 claims |
| NovartisEntresto | $16,495 | $267,881229 claims |
| PfizerEliquis | $121 | $267,287248 claims |
| Johnson & JohnsonXarelto | $118,780 | $234,883190 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $8,877 | $60,22953 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $5,938 | $48,49563 claims |
| AstraZenecaFarxiga, Brilinta | $58 | $46,78149 claims |
| MerckVerquvo | $82,140 | $37,98630 claims |
| Novo NordiskOzempic | $115,694 | $29,33626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Dallas
- Robert GottliebDallas$717K
- Shelley HallDallas$254K
- Maryjane FarrDallas$148K
- Claudius MahrDallas$87K
- Kartik TelukuntlaDallas$80K
- Song LiDallas$27K
- Farah Al-SaffarDallas$24K
- Srikant PatlollaDallas$23K
- Nicholas HendrenDallas$12K
- Brian HsiDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.